pCODR

Prostate Cancer Canada (PCC) is a proud patient group member of the pan-Canadian Oncology Drug Review (pCODR). pCODR was established by Canada's provincial and territorial Ministries of Health (with the exception of Quebec) to assess cancer drug therapies and make recommendations to guide drug-funding decisions. PCC participates in this process by collecting feedback from patients and caregivers and submitting this feedback to pCODR.

To learn more about pCODR please visit their website.


Current Drugs Under Review


No drugs are being reviewed at this time.


If you have any questions, please contact drugcoverage@prostatecancer.ca 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More

Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More


Click here for news archive